financetom
Business
financetom
/
Business
/
Cars.com misses Q2 revenue estimates, raises share buyback target
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cars.com misses Q2 revenue estimates, raises share buyback target
Aug 7, 2025 4:59 AM

Overview

* Cars.com ( CARS ) Q2 revenue misses analyst expectations, adjusted EPS beats, per LSEG data

* Co repurchased 2.1 mln shares, raising FY 2025 buyback target to $70-$90 mln

* Revenue for Q2 totaled $178.7 mln, roughly flat yr/yr

Outlook

* Company anticipates low-single digit revenue growth for H2 2025

* Company reaffirms full-year adjusted EBITDA margin guidance of 29% to 31%

Result Drivers

* DEALER REVENUE - Subscription-based Dealer revenue was down 1% year-over-year, primarily reflecting changes in customer and product mix

* ACCUTRADE ADOPTION - AccuTrade appraisals grew 45% year-over-year, reflecting increased product adoption and customer engagement

* OPERATIONAL EFFICIENCIES - Cost management and operational efficiencies helped reduce operating expenses, contributing to a high adjusted EBITDA margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $178.70 $179.40

Revenue mln mln (7

Analysts

)

Q2 Beat $0.41 $0.07 (6

Adjusted Analysts

EPS )

Q2 Net $7 mln

Income

Q2 $50.90

Adjusted mln

EBITDA

Q2 $152.70

Adjusted mln

Operatin

g

Expenses

Q2 $163.50

Operatin mln

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the online services peer group is "buy"

* Wall Street's median 12-month price target for Cars.com Inc ( CARS ) is $15.25, about 13.9% above its August 6 closing price of $13.13

* The stock recently traded at 28 times the next 12-month earnings vs. a P/E of 14 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Update: Rumble Shares Soar After Agreeing to $775 Million Strategic Investment From Tether
Update: Rumble Shares Soar After Agreeing to $775 Million Strategic Investment From Tether
Dec 23, 2024
09:55 AM EST, 12/23/2024 (MT Newswires) -- (Updates with recent stock movement in the headline and first paragraph.) Rumble (RUM) shares were up almost 61% Monday morning after the companies said late Friday that Rumble agreed to a $775 million strategic investment from cryptocurrency firm Tether. Under the terms, Tether will purchase 103.3 million of Rumble's shares for $7.50 apiece....
Iamgold Amends, Upsizes Credit Facility
Iamgold Amends, Upsizes Credit Facility
Dec 23, 2024
09:55 AM EST, 12/23/2024 (MT Newswires) -- Iamgold ( IAG ) said Monday that the company and its group of lenders have amended its existing secured revolving credit facility, extending its term to four years through Dec. 20, 2028. The facility size has also been increased to $650 million from $425 million, the company said, adding that the facility will...
SPX Technologies to Acquire Kranze Technology Solutions for $350 Million
SPX Technologies to Acquire Kranze Technology Solutions for $350 Million
Dec 23, 2024
09:56 AM EST, 12/23/2024 (MT Newswires) -- SPX Technologies ( SPXC ) said Monday it has agreed to acquire Kranze Technology Solutions for about $350 million in cash. The deal, expected to close in Q1 2025, will add KTS to SPX's Communication Technologies platform within its Detection & Measurement segment, the company said. KTS is expected to generate around $90...
Zura Bio Begins Phase 2 Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Zura Bio Begins Phase 2 Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
Dec 23, 2024
09:51 AM EST, 12/23/2024 (MT Newswires) -- Zura Bio ( ZURA ) said Monday that it has begun a phase 2 study evaluating tibulizumab as a treatment for adult patients with systemic sclerosis. The immunology company said the study includes a 24-week efficacy period and a 28-week open-label extension. It also said the primary endpoint of the trial is the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved